Objective: An accurate biomarker of successful tuberculosis (TB) treatment would be a major advance, and ultimately assist in control of the TB pandemic. Currently available commercial immunodiagnostic tests are not adequate for this purpose.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Pathology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2016 Published by Elsevier Inc.